302 related articles for article (PubMed ID: 36119020)
1. Targeting immunometabolism mediated by the IDO1 Pathway: A new mechanism of immune resistance in endometrial cancer.
Passarelli A; Pisano C; Cecere SC; Di Napoli M; Rossetti S; Tambaro R; Ventriglia J; Gherardi F; Iannacone E; Venanzio SS; Fiore F; Bartoletti M; Scognamiglio G; Califano D; Pignata S
Front Immunol; 2022; 13():953115. PubMed ID: 36119020
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
3. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
5. Trial watch: IDO inhibitors in cancer therapy.
Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
[TBL] [Abstract][Full Text] [Related]
6. The Role of Kynurenines Produced by Indolamine-2,3-Dioxygenase 1 in Sepsis.
Lerch S; Schefold JC; Spinetti T
Pharmacology; 2022; 107(7-8):359-367. PubMed ID: 35413710
[TBL] [Abstract][Full Text] [Related]
7. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
8. Quantification of IDO1 enzyme activity in normal and malignant tissues.
Zhai L; Ladomersky E; Bell A; Dussold C; Cardoza K; Qian J; Lauing KL; Wainwright DA
Methods Enzymol; 2019; 629():235-256. PubMed ID: 31727243
[TBL] [Abstract][Full Text] [Related]
9. Pathogenetic Interplay Between IL-6 and Tryptophan Metabolism in an Experimental Model of Obesity.
Mondanelli G; Albini E; Orecchini E; Pallotta MT; Belladonna ML; Ricci G; Grohmann U; Orabona C
Front Immunol; 2021; 12():713989. PubMed ID: 34394118
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
11. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
12. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
13. IDO1 in cancer: a Gemini of immune checkpoints.
Zhai L; Ladomersky E; Lenzen A; Nguyen B; Patel R; Lauing KL; Wu M; Wainwright DA
Cell Mol Immunol; 2018 May; 15(5):447-457. PubMed ID: 29375124
[TBL] [Abstract][Full Text] [Related]
14. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia
Atene CG; Fiorcari S; Mesini N; Alboni S; Martinelli S; Maccaferri M; Leonardi G; Potenza L; Luppi M; Maffei R; Marasca R
Front Immunol; 2022; 13():832263. PubMed ID: 35371054
[TBL] [Abstract][Full Text] [Related]
16. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process.
Salminen A
Ageing Res Rev; 2022 Mar; 75():101573. PubMed ID: 35085834
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-Dioxygenase (IDO) Activity: A Perspective Biomarker for Laboratory Determination in Tumor Immunotherapy.
Yang P; Zhang J
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509627
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
19. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
20. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
